Drug
Nerandomilast (JASCAYD®)
Status:
To Patients
Condition:
Other ILD
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Detail
Nerandomilast (JASCAYD®) is an oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects. Nerandomilast (JASCAYD®) treats patients with progressive pulmonary fibrosis (PPF).
Study Purpose
Nerandomilast (JASCAYD®) has received FDA approval. The drug is currently undergoing evaluation in additional clinical trials.